Ukr.Biochem.J. 2025; Volume 97, Issue 5, Sep-Oct, pp. 58-71

doi: https://doi.org/10.15407/ubj97.05.058

Department of Cell Signaling relay race of time: from studying the structure and function of individual proteins to analyzing protein–protein interaction networks

10.11.2025   Uncategorized

O. O. Hudkova, L. B. Drobot*

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine,
Department of Cell Signaling, Kyiv;
*e-mail: drobot@biochem.kiev.ua

Received: 30 September 2025; Revised: 08 October 2025;
Accepted: 30 October 2025; Available on-line: 02 December 2025

The review presents the history of establishment, key achievements, and development prospects of the Department of Cell Signaling at the Palladin Institute of Biochemistry of the NAS of Ukraine. As a structural unit of the institution, the Department was established in 2018 through the merger of two separate subdivisions: one of the oldest, the Department of Metabolic Regulation (founded in 1944), and the youngest, the Laboratory of Cell Signaling (founded in 2006). From its inception, the department’s primary research focus has been the study of the structure and functions of individual animal and microbial proteins. Significant contributions to the fundamental and applied achievements during that period were made by leaders of the Department, Dr.Sci., Professor Szörényi E.T., and Academician of NASU Huliy M.F., which were recognized with State Prizes of the USSR and the Ukrainian SSR (1953, 1978, 1988). Considerable attention has been given­ to transforming the department’s research direction to meet modern standards in molecular cell biology, a shift logically linked to the work of the unified unit under the leadership of Dr.Sci., Professor L.B. Drobot. This transformation involved not only the formal merger of two teams but also the integration of their scientific accomplishments and intellectual potential, combining traditional and innovative research approaches. The scientific paths of both subdivisions inevitably converged, necessitating joint investigations in response to contemporary challenges and societal demands. The department’s central focus became the elucidation of signaling mechanisms involved in the coordinated regulation of proliferation, differentiation, and apoptosis in normal and transformed cells with the participation of adaptor/scaffold protein Ruk/CIN85. Through the efforts of the department’s researchers, the pivotal role of Ruk/CIN85 in controlling the plasticity of tumor cells of various origins was convincingly demonstrated–particularly in the development of cancer stem cell traits, chemoresistance, tumor progression, and/or differentiation.

Keywords: , , , ,

References:

  1. Soreni ET. On the influence of training on the respiratory functions of muscle tissue. Ukr Biokhim Zhurn. 1936;9:193. (In Russian).
  2. Soreni ET, Chepinoga OP. About breathing and respiratory enzymes of tired muscles. Ukr Biokhim Zhurn. 1936;9:989. (In Russian).
  3. Soreni ET. Protein-bound phosphate as a product of ATP breakdown. Dop Akad Nauk URSR. 1946;52:323.
  4. Soreni ET, Degtyar RG, Dvornikova PD.Crystalline isolation and description of the enzyme adenosine triphosphate targinase. Ukr Biokhim Zhurn. 1948;21(2):118. (In Russian).
  5. Guly MF. Protein is the basis of life. K.,1962. 60 p. (In Russian).
  6. Gulyy MF. Protein biosynthesis. K.: Izd-vo AN USSR, 1963. 204 p. (In Russian).
  7. A.C. 353956 SU, IPC С 12d 13/10; С 07g 7/028. Method for isolation of purified catalase preparation. Dehtyar RG, Guly MF, Gudkova LB, Vakulenko VA.; applicant: Palladin Institute of Biochemistry, NAS of Ukraine, No 1634957/28-13; appl. 19.03.1971; publ. 09.10.72, Bul. No 30, discription publ. 09.11.72.
  8. A.C. 160618 SU, IPC G 01n, 42/3. Method for enzyme assessment of glucose in biological fluids. Guly MF, Dehtyar RG. No 808745/31-16; appl. 17.12.62; publ. 1964, Bul. No 4.
  9. A.C. 204962 SU, IPC С 12k; 6a 22/04. Method for obtaining catalase and glucose oxidase enzyme preparations. Guly MF, Dehtyar RG, Chumachenko YV, Lototskaya LS, Pidoplichko NM, Nikolskaya EA, Bilay VI.; applicant: Palladin Institute of Biochemistry, NAS of Ukraine, No 1098225/18-13; appl. 20.08.66; publ. 13.11.67, Bul. No 23, description publ. 15.01.68.
  10. Guly MF, Melnichuk DA. The role of carbon dioxide in the regulation of metabolism in heterotrophic organisms. K.: Naukova dumka, 1977. 172 p. (In Russian).
  11. Pat. 2070044 RU, IPC5 A 61 K 33/06, A 61 K 33/10, A 61 K 33/30, A 61 K 33/32. Method for obtaining the preparation that stimulates metabolic processes. Guly MF, Melnichuk DA, Stogniy NA, Shevtsova NF, Tischenko GN, Zagoriy VA, Denisov MD, Zabarskiy OSh, Tarakhovskiy ML, Tsypkun AG, Denisova MF.; applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine (UA); No 925064547; appl. 16.06.92; publ. 10.12.96, Bul. No 34
  12. Pat. 13788 А UА, IPC5 А 61 K 33/06, А 61 K 33/10, А 61 K 33/30, А 61 K 33/32. Adaptogenic preparation and method of its obtaining. Guly MF, Melnichuk DA, Stogniy NA, Shevtsova NF, Tischenko GN, Zagoriy VA, Denisov MD, Zabarskiy OSh, Tarakhovskiy ML, Tsypkun AG, Denisova MF.; applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine (UA), Pharmaceutical Firm Darnitsa (UА); Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine (UA). No 93070757; appl. 10.03.93; publ. 25.04.97, Bul. No 2.
  13. Pat. 15136 UА, IPC5 А 61 K 31/185, 31/195, 31/79. Method for producing of anti-alcohol drug Medikhronal. Guly MF, Melnichuk DA, Sinitskiy VM, Stogniy NA, Kovtun TV, Silonova NV, Shevtsova NF, Sushkova VV, Kasyanova NM, Zagoriy VA, Denisov MD, Zabarskiy OSh.; applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine (UA), Pharmaceutical Firm Darnitsa. No 93007398; appl. 26.10.93; publ. 30.08.99, Bul. No 5.
  14. Pat. 74751 UА. IPC6 А 61 K 31/785; А 61 Р 7/00; А 61 Р 19/00; А 61 35/00; А 61 K 31/79. Pharmaceutical complex formulation Korectin and method for its obtaining. Guly MF, Komisarenko SV, Babeshko VG, Volodina TT, Bruslova KM, Drozdova VD, Petrun LM, Dzvonkevich ND, Pechenova TM, Chernyaev SV, Goncharuk PG, Marchenko LV.; applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine. No 2004 1210708; appl. 27.12.2004; publ. 16.01.2006, Bul. No 1.1.
  15. A.C. 1621938 SU, IPC5 А 1 А 61 K 31/195. Method for treating bone diseases upon acute leukemia in children. Guly MF, Babeshko VG, Drozdova VD, Volodina TT, Pechenova TN, Sushkova VV, Dzvonkevich ND. No 4433137/14; appl. 30.05.88; publ. 23.01.91, Bul. No 3.
  16. Pat. 47703 UА, IPC9 A61K 31/375, A61K 31/19, A61K 31/194, A61K 9/20, A61P 25/32. Preparation for reducing of alcohol intoxication, hangover syndrome and drug addiction upon alcohol abuse.Dmytrenko MP, Komisarenko SV, Kishko TO, Shandrenko SG.; applicant and 121 patent owner: Palladin Institute of Biochemistry, NAS of Ukraine (UA). No u200906868; appl. 01.07.2009; publ. 25.02.2010, Bul. No 4.
  17. Buryy OM, Dmytrenko MP, ​​Shandrenko SG. Modern methods of diagnosing Helicobacter pylori. Ukr J Minimally Invasive Endosc Sur. 2011;15(2):31-33. (In Ukrainian).
  18. Chumachenko IM, Kapustyanenko LG, Shandrenko SG. Blood labile iron effect on nitrosative stress development under rat experimental rhabdomyolysis. Biol Stud. 2012;6(3):105-114. (In Ukrainian). CrossRef
  19. Tokarchuk KO, Kapustianenko LH, Shandrenko SH. The role of aldehydes in development of oxidative stress under rhabdomyolysis in rats. Fiziol Zh. 2013;59(1):25-31. (In Ukrainian). PubMed, CrossRef
  20. Volodina TT, Dzvonkevych ND, Petrun’ LM, Krysiuk IP, Popova NM, Shandrenko SH, Dmytrenko MP. Altered collagene characteristics and lysyl oxidase activity in lathyrism. Fiziol Zh. 2011;57(3):62-68. (In Ukrainian). PubMed, CrossRef
  21. Gudkova OO, Latyshko NV, Shandrenko SG. Amine oxidases as important agents of pathological processes of rhabdomyolysis in rats. Ukr Biochem J. 2016;88(1):79-87. CrossRef
  22. Tokarchuk K, Krysyuk I, Shandrenko S. Changes of carbonyl stress parameters in rats with diabetes and rhabdomyolysis. Int J Biochem Res Rev. 2015;6(4):151-159. CrossRef
  23. Hudkova O, Luhovskyi S, Drobot L, Latyshko N. Involvement of Cu-containing amine oxidases in the development of lung pathology in ovalbumin-induced bronchial asthma in guinea pigs. Ukr Biochem J. 2022;94(3):26-38. CrossRef
  24. Linghu H, Tsuda M, Makino Y, Sakai M, Watanabe T, Ichihara S, Sawa H, Nagashima K, Mochizuki N, Tanaka S. Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS. Oncogene. 2006;25(25):3547-3556. PubMed, CrossRef
  25. Dai Y, Qi L, Zhang X, Li Y, Chen M, Zu X. CrkI and p130(Cas) complex regulates the migration and invasion of prostate cancer cells. Cell Biochem Funct. 2011;29(8):625-629. PubMed, CrossRef
  26. Gout I, Middleton G, Adu J, Ninkina NN, Drobot LB, Filonenko V, Matsuka G, Davies AM, Waterfield M, Buchman VL. Negative regulation of PI 3-kinase by Ruk, a novel adaptor protein. EMBO J. 2000;19(15):4015-4025. PubMed, PubMedCentral, CrossRef
  27. Shuvaeva GYu, Bobak YaP, Mayevska OM, Igumentseva NI, Rzhepetsky Yu, Mashtalir OM, Pospishil YuO, Shulyak OV, Vozianov SO, Drobot LB. Expression of the adapter protein Ruk/CIN85 in human kidney tumors. Exp Clin Physiol Biochem. 2004;4:92-99. (In Ukrainian).
  28. Mayevska O, Shuvayeva H, Igumentseva N, Havrylov S, Basaraba O, Bobak Y, Barska M, Volod’ko N, Baranska J, Buchman V, Drobot L. Expression of adaptor protein Ruk/CIN85 isoforms in cell lines of various tissue origins and human melanoma. Exp Oncol. 2006;28(4):275-281. PubMed
  29. Basaraba OI, Pasichnyk HV, Kyrylkova KV, Bobak YaP, Samoylenko AA, Marchenko SM, Marina VN, Kolomiytsev VI, Drobot LB. Expression features of adapter proteins Ruk/CIN85 and CD2AP/CMS in normal and transformed human thyroid tissues. Exp Clin Physiol Biochem. 2008;(3):19-25. (In Ukrainian).
  30. Basaraba O, Bobak YA, Shuvayeva H, Marchenko S, Mayevsʹka O, Ihumentseva N, Volodʹko N, Bukhman V, Drobot L. Study of the expression of adapter proteins Ruk/CIN85 and CD2AP/CMS in human uterine tumors. Clin Exp Pathol. 2009;8(4):125-130. (In Ukrainian).
  31. Kit YY, Drel VR, Petriv OI, Kovalyova VA, Shuvaeva GY, Palivoda OY, Vovk EI, Bobak YP, Rzeszowska-Wolny J, Gout IT, Buchman VL, Drobot LB. Adaptor protein Ruk1 forms protein-protein complexes with endonuclease activity in HEK293 cells. Biochemistry (Mosc). 2003;68(7):810-815. PubMed, CrossRef
  32. Nikolaienko O, Skrypkina I, Tsyba L, Fedyshyn Y, Morderer D, Buchman V, de la Luna S, Drobot L, Rynditch A. Intersectin 1 forms a complex with adaptor protein Ruk/CIN85 in vivo independently of epidermal growth factor stimulation. Cell Signal. 2009;21(5):753-759. PubMed, CrossRef
  33. Havrylov S, Rzhepetskyy Y, Malinowska A, Drobot L, Redowicz MJ. Proteins recruited by SH3 domains of Ruk/CIN85 adaptor identified by LC-MS/MS. Proteome Sci. 2009;7:21. PubMed, PubMedCentral, CrossRef
  34. Rzepetsky YuA, Samoylenko AA, Kukharenko OP, Mikhalap SV, Sidorenko SP, Hausser A, Drobot LB. Protein kinase d interacts with adaptor protein Ruk/CIN85 and phosphorylates it. Biol Stud. 2009;3(3):17-28. (In Ukrainian). CrossRef
  35. Samoylenko AA. Enhancement of the expression of adaptor protein Ruk/CIN85 in MCF-7 cells under the action of insulin and IGF-1. Rep Nat Acad Sci Ukraine. 2011;(4):158-162. (In Ukrainian).
  36. Samoylenko A, Dimova EY, Kozlova N, Drobot L, Kietzmann T. The adaptor protein Ruk/CIN85 activates plasminogen activator inhibitor-1 (PAI-1) expression via hypoxia-inducible factor-1alpha. Thromb Haemost. 2010;103(5):901-909. PubMed, CrossRef
  37. Samoylenko AA, Byts NV, Pasichnyk GV, Kozlova NV, Bazalii AV, Gerashchenko DS, Shandrenko SG, Vorotnikov AV, Kietzmann T, Komisarenko SV, Drobot LB. Recombinant lentivirus-mediated silencing of adaptor protein Ruk/CIN85 expression influences biological responses of tumor cells. Biotechnol Acta. 2013;6(4):182-189. (In Ukrainian). CrossRef
  38. Kozlova N, Mennerich D, Samoylenko A, Dimova EY, Koivunen P, Biterova E, Richter K, Hassinen A, Kellokumpu S, Manninen A, Miinalainen I, Glumoff V, Ruddock L, Drobot LB, Kietzmann T. The Pro-Oncogenic Adaptor CIN85 Acts as an Inhibitory Binding Partner of Hypoxia-Inducible Factor Prolyl Hydroxylase 2. Cancer Res. 2019;79(16):4042-4056. PubMed, CrossRef
  39. Samoylenko A, Vynnytska-Myronovska B, Byts N, Kozlova N, Basaraba O, Pasichnyk G, Palyvoda K, Bobak Y, Barska M, Mayevska O, Rzhepetsky Y, Shuvayeva H, Lyzogubov V, Usenko V, Savran V, Volodko N, Buchman V, Kietzmann T, Drobot L. Increased levels of the HER1 adaptor protein Rukl/CIN85 contribute to breast cancer malignancy. Carcinogenesis. 2012;33(10):1976-1984. PubMed, CrossRef
  40. Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 2011;10(17):3003-3015. PubMed, PubMedCentral, CrossRef
  41. Pat. 130483 Ukrayina MPK 2018.01: C121/6886, C12N 5/10, C12N 5/095, C12N 5/09, C12N 5/16. Use of stable tumor cell sublines as models for testing antitumor drugs aimed at detecting cancerous stem cells. DrobotL.B., Komisarenko S.V., Pasichnyk H.V., Horak I.R., Herashchenko D.S. Applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine. – No. u201806310; declared 06.06.2018; publisher 10.12.2018, Bull. No 23. (In Ukrainian).
  42. Pasichnyk GV, Povorozniuk OО, Gorak IR, Gerashchenko DS, Ponomarenko OV, Samoylenko AA, Byts NV, Drobot LB. Overexpression of adaptor protein Rukl/CIN85 in human breast adenocarcinoma cell line MCF-7 is accompanied by increased
    chemoresistance. Rep Nat Acad Sci Ukraine. 2013;(12):149-156.
  43. Horak ІR, Pasichnyk GV, Gerashchenko DS, Knopfova L, L Borsig, Drobot LB. Adaptor protein Ruk/CIN85 modulates manifestation of cancer stem cells (CSCs) features in mouse breast adenocarcinoma 4T1 cells. Rep Nat Acad Sci Ukraine. 2018;(12):101-109. CrossRef
  44. Horak IR, Gerashchenko DS, Drobot LB. Adaptor protein Ruk/CIN85 modulates resistance to doxorubicin of murine 4T1 breast cancer cells. Ukr Biochem J. 2018;90(3):94-100. CrossRef
  45. Drobot LB, Samoylenko AA, Vorotnikov AV, Tyurin-Kuzmin PA, Bazalii AA, Kietzmann T, Tkachuk VA, Komisarenko SV. Reactive oxygen species in signal transduction. Ukr Biochem J. 2013;85(6): 208-217. CrossRef
  46. Bazalii АV, Vorotnikov AV, Тyurin-Кuzmin PA, Тkachuk VА, Kоmisarenko SV, Drobot LB. Recombinant fluorescent sensor of hydrogen peroxide HyPer fused with adaptor protein Ruk/CIN85: desining of expression vector and functional characterization. Biotechnol Acta. 2015;8(5):19-26. CrossRef
  47. Bazalii AV, Horak IR, Pasichnyk GV, Komisarenko SV, Drobot LB. Transcriptional regulation of NOX genes expression in human breast adenocarcinoma MCF-7 cells is modulated by adaptor protein Ruk/CIN85. Ukr Biochem J. 2016;88(1):119-125. CrossRef
  48. Bazalii AV, Drobot LB, Komisarenko SV. Apocynin attenuates motility and induces transition from sustained to transient EGF-dependent Akt activation in MCF-7 cells that overexpress adaptor protein Ruk/CIN85. Biopolym Cell. 2016;32(1):21-25. CrossRef
  49. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003;3(5):362-374. PubMed, CrossRef
  50. Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013;27(20):2192-2206. PubMed, PubMedCentral, CrossRef
  51. Campos-Sánchez E, Cobaleda C. Tumoral reprogramming: Plasticity takes a walk on the wild side. Biochim Biophys Acta. 2015;1849(4):436-447. PubMed, CrossRef
  52. Ye X, Weinberg RA. Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends Cell Biol. 2015;25(11):675-686. PubMed, PubMedCentral, CrossRef
  53. Bhatia S, Monkman J, Toh AKL, Nagaraj SH, Thompson EW. Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. Biochem J. 2017;474(19):3269-3306. PubMed, CrossRef
  54. Liao TT, Yang MH. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness. Mol Oncol. 2017;11(7):792-804. PubMed, PubMedCentral, CrossRef
  55. O’Brien-Ball C, Biddle A. Reprogramming to developmental plasticity in cancer stem cells. Dev Biol. 2017;430(2):266-274. PubMed, CrossRef
  56. Panková K, Rösel D, Novotný M, Brábek J. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cell Mol Life Sci. 2010;67(1):63-71. PubMed, PubMedCentral, CrossRef
  57. Škovierová H, Okajčeková T, Strnádel J, Vidomanová E, Halašová E. Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review). Int J Mol Med. 2018;41(3):1187-1200. PubMed, PubMedCentral, CrossRef
  58. Babich LG, Shlykov SG, Yesypenko OA, Bavelska-Somak AO, Zahoruiko AG, Horak IR, Drobot LB, Kosterin SO. Calix[4]arene chalcone amide C-1011 elicits differential effects on the viability of 4T1 mouse breast adenocarcinoma cells with different levels of adaptor protein Ruk/CIN85 expression. Ukr Biochem J. 2022;94(2):24-30. CrossRef
  59. Bekala MI, Horak IR, Gudkova OO, Latyshko NV, Tokarchuk KO, Geraschenko DS, Shkoda MO, Drobot LB. Adaptor protein Ruk/CIN85 is involved in the glucose metabolism reprogramming in breast cancer cells. Biotechnol Acta. 2022;15(2):47-48. CrossRef
  60. Korshun RS, Hudkova OO, Latyshko NV, Kishko TO, Horak IR, Drobot LB. Adaptor protein Ruk/CIN85 participates in the metabolic control of human breast adenocarcinoma MCF-7 cells. Biotechnol Acta. 2022;15(2)58-59. CrossRef
  61. Garifulin OM, Zaiets IV, Kosach VR, Horak IR, Khoruzhenko AI, Gotsulyak NYa, Savinska LO, Kroupskaya IV, Martsynyuk MYe, Drobot LB, Filonenko VV. Alterations in S6K1 isoforms expression induce Epithelial to Mesenchymal Transition and Estrogen Receptor 1 Silencing in human breast adenocarcinoma MCF-7 cells. Biopolym Cell. 2023;39(3):189-200. CrossRef
  62. Zhyvolozhnyi AYu, Horak IR, Skaterna TD, Khudiakova OV, Vainio SJ, Samoylenko AA, Drobot LB. Composition of EVs markers under normoxic and hypoxic conditions depends on the expression level of adaptor protein Ruk/CIN85 in mouse renal carcinoma Renca cells. Biopolym Cell. 2021;37(5):325-334. CrossRef
  63. Zhyvolozhnyi AYu, Horak IR, Geraschenko DS, Gomozkova MO, Hudkova OO, Vainio SJ, Samoylenko AA, Drobot LB. Extracellular vesicles produced by mouse breast adenocarcinoma 4T1 cells with up- or down-regulation of adaptor protein Ruk/CIN85 differentially modulate the biological properties of 4T1 WT cells. Ukr Biochem J. 2021;93(6):46-54. CrossRef
  64. Dian L, Xu Z, Sun Y, Li J, Lu H, Zheng M, Wang J, Drobot L, Horak I. Berberine alkaloids inhibit the proliferation and metastasis of breast carcinoma cells involving Wnt/β-catenin signaling and EMT. Phytochemistry. 2022;200:113217. PubMed, CrossRef
  65. Horak I, Prylutska S, Krysiuk I, Luhovskyi S, Hrabovsky O, Tverdokhleb N, Franskevych D, Rumiantsev D, Senenko A, Evstigneev M, Drobot L, Matyshevska O, Ritter U, Piosik J, Prylutskyy Y. Nanocomplex of berberine with C60 fullereneis a potent suppressor of Lewis lung carcinoma cells invasion in vitro and metastatic activity in vivo. Materials (Basel). 2021;14(20):6114. PubMed, PubMedCentral, CrossRef
  66. Grebinyk A, Prylutska S, Grebinyk S, Evstigneev M, Krysiuk I, Skaterna T, Horak I, Sun Y, Drobot L, Matyshevska O, Prylutskyy Y, Ritter U, Frohme M. Antitumor efficiency of the natural alkaloid berberine complexed with C60 fullerene in Lewis lung carcinoma in vitro and in vivo. Cancer Nanotechnol. 2021;12(1):24. CrossRef
  67. Horak I, Skaterna T, Lugovskyi S, Krysiuk I, Tykhomyrov A, Prylutska S, Tverdokhleb N, Senenko A, Cherepanov V, Drobot L, Matyshevska O, Ritter U, Prylutskyy Y. Antimetastatic lung cancer therapy using alkaloid Piperlongumine noncovalently bound to С60 fullerene. J Drug Deliv Sci Technol. 2024;92:105275. CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.